Literature DB >> 9649458

The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease.

J J Vicari1, R M Peek, G W Falk, J R Goldblum, K A Easley, J Schnell, G I Perez-Perez, S A Halter, T W Rice, M J Blaser, J E Richter.   

Abstract

BACKGROUND & AIMS: The role of Helicobacter pylori in the pathogenesis of gastroesophageal reflux disease (GERD) is unknown. We determined the prevalence of cagA-positive (cagA+) H. pylori strains in patients with GERD or its complications compared with controls of similar age.
METHODS: A total of 153 consecutive patients with GERD, Barrett's esophagus, and Barrett's esophagus complicated by dysplasia or adenocarcinoma were compared with 57 controls who underwent upper endoscopy for reasons other than GERD. H. pylori infection and CagA antibody status were determined by histology and enzyme-linked immunosorbent assay.
RESULTS: H. pylori prevalence was lower (34%) in patients with GERD and its sequelae than in the control group (45.6%)(P = 0.15). Regardless of the group, increasing age was associated with higher prevalence of H. pylori (P = 0.003). When compared with controls (42.3%), the prevalence of cagA+ H. pylori strains decreased (P = 0.008) in patients with more severe complications of GERD (GERD, 36.7% [nonerosive GERD, 41.2%; erosive GERD, 30.8%]; Barrett's esophagus, 13.3%; and Barrett's with adenocarcinoma/dysplasia, 0%).
CONCLUSIONS: Prevalence of H. pylori in patients with GERD and its sequelae was lower but not significantly different than that of a control group. However, patients carrying cagA+ strains of H. pylori may be protected against the complications of GERD, especially Barrett's esophagus and its associated dysplasia and adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9649458     DOI: 10.1016/s0016-5085(98)70364-6

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  78 in total

Review 1.  Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation.

Authors:  D McNamara; C O'Morain
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 2.  Helicobacter pylori-reflections for the next millennium.

Authors:  G N Tytgat
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

Review 3.  Treatment of Helicobacter pylori.

Authors:  A Harris
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

4.  The phenotype of gastric mucosa coexisting with Barrett's oesophagus.

Authors:  M Rugge; V Russo; G Busatto; R M Genta; F Di Mario; F Farinati; D Y Graham
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

5.  Gastroesophageal reflux disease and esophageal cancer: new respect for an old disease.

Authors:  J E Richter
Journal:  Curr Gastroenterol Rep       Date:  2000-02

6.  Helicobacter pylori infection and long term proton pump inhibitor therapy.

Authors:  K E L McColl
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

Review 7.  Cancer of the esophagogastric junction: epidemiology and pathogenesis.

Authors:  Prateek Sharma
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

8.  CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer.

Authors:  M Kudo; O Gutierrez; H M T El-Zimaity; H Cardona; Z Z Nurgalieva; J Wu; D Y Graham
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

9.  RELATIONSHIP BETWEEN THE PRESENCE OF HELICOBACTER PYLORI WITH INFLAMMATORY ENDOSCOPIC CHANGES IN GASTRODUODENAL MUCOSA.

Authors:  Irma Cláudia Saboya Ribeiro; Luiz Fernandao Kubrusly; Paulo Afonso Nunes Nassif; Patrícia Fernanda Saboya Ribeiro; Rodrigo de Oliveira Veras; Aline Neppel
Journal:  Arq Bras Cir Dig       Date:  2016 Jul-Sep

10.  Iron deficiency accelerates Helicobacter pylori-induced carcinogenesis in rodents and humans.

Authors:  Jennifer M Noto; Jennifer A Gaddy; Josephine Y Lee; M Blanca Piazuelo; David B Friedman; Daniel C Colvin; Judith Romero-Gallo; Giovanni Suarez; John Loh; James C Slaughter; Shumin Tan; Douglas R Morgan; Keith T Wilson; Luis E Bravo; Pelayo Correa; Timothy L Cover; Manuel R Amieva; Richard M Peek
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.